We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0G8X market cap is 8.67B. The company's latest EPS is SEK -6.8328 and P/E is -28.01.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 712k | 651k | 844k | 1.15M | 1.8M |
| Operating Income | -114.35M | -134.68M | -166.74M | -191.21M | -296.46M |
| Net Income | -114.52M | -146.03M | -155.97M | -168.09M | -309.44M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 419.37M | 661.18M | 493.81M | 300.59M | 98.68M |
| Total Liabilities | 61.76M | 61.78M | 59.91M | 56.79M | 31.69M |
| Total Equity | 357.61M | 599.4M | 433.9M | 243.8M | 66.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -91.95M | -120.7M | -152.65M | -175.58M | -147.06M |
| Investing | -36.6M | -46.96M | -23.83M | -1.62M | 3.2M |
| Financing | 5.76M | 373.58M | -5.27M | -5.11M | 114.74M |
| Market Cap | 8.67B |
| Price to Earnings Ratio | -28.01 |
| Price to Sales Ratio | 4.81k |
| Price to Cash Ratio | 112.88 |
| Price to Book Ratio | 129.39 |
| Dividend Yield | - |
| Shares Outstanding | 45.29M |
| Average Volume (1 week) | 7.63k |
| Average Volume (1 Month) | 4.78k |
| 52 Week Change | 0.00% |
| 52 Week High | 191.40 |
| 52 Week Low | 191.40 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Immunovia Ab (publ) |
| Address |
medicon village lund 223 63 |
| Website | https://www.immunovia.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
